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Randomized phase II trials demonstrated superiority of targeted therapy with tyrosine kinase inhibitors 
over cytokine-based therapy as first-line therapy for metastatic renal cel carcinoma. However, the rate of 
complete response (CR) with targeted therapy is smaller than that with cytokine-based therapy. A 47-year-
old man w出 referredto our hospital with a 12 cm left renal tumor and polycythemia. He was diagnosed 
with renal cancer, cT3aNOMl, with multiple lung metastases. He underwent cytoreductive nephrectomy, 
with the histopathological diagnosis of clear cel renal cel carcinoma, Fuhrman nuclear grade 2, INFb, pT2b. 
Three months postoperatively, spontaneous regression of lung metastases was observed. Seventeen months 
postoperatively, a 17×13 mm retroperitoneal tumor facing the pancreas recurred. CR of the recurrent 
tumor was achieved by targeted therapy with sunitinib for 12 months. This CR was maintained for 32 
months after the discontinuation of targeted therapy with sunitinib. 
(Hinyokika Kiyo 64: 483 487, 2018 DOI: 10.14989/ActaUroリap_64_12_483) 















(Hb: 20.1 g/dl)の精査の際に偶発的に径 12cmの左
腎腫癌を指摘され，同年10月29日に当科を受診され
た．
血液検査所見： WBC7,100 (/μl), Hb 20.1 (g/ 
di), PLT 22. 7 (104 /μI), CRP I. 57 (mg/di), LDH 
224 (mg/dl），補正Ca9. 3 (mg/dl). TP 7. 3 (g/dl). 
























Fig. 1. a: Contrast-enhanced CT scan showed a 12 cm renal tumor in the left kidney (left: 
axial section, right: sagittal section). b : Representative images of lung metastases 
(arrow). 
INF p, lyO, vO, eg, fc I, imO, re-inf!, rp・infD, s-
infD, pT2bと診断した（Fig.2a, b）.転移性腎細胞癌
の予後に関するリスク分類では MemorialSloan 
Kettering Cancer Center (MSKCC）分類は初診時から
治療開始までの期間のみが該当し intermediateriskで










































Fig. 2. a : Macroscopic fi吋ingsof出esurgical 
specimen ; 12 cm yellow tumor with central 
necrosis. b : Microscopic findings of the 
surgical specimen ; Clear cel renal cel carci-


















Fig. 3. a: A 12×10 mm retroperitoneal recurrent 
tumor facing the pancreas (11 months post-
operatively). b : A 17×13 mm retroper-
itoneal recurrent tumor facing the pancreas 
(17 months postoperatively). c: A 7×4 
mm retroperitoneal fibrosis after 12 months 





























に対するイ ンターフエロ ン療法での CR獲得率は
12%であると報告されている6）.一方で転移性腎細胞
癌に対する分子標的薬治療の CR獲得率は第3相臨
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